Cargando…

Expression changes of ER, PR, HER2, and Ki-67 in primary and metastatic breast cancer and its clinical significance

OBJECTIVE: To explore the altered expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and cell proliferation index (Ki-67) in primary and metastatic breast cancer lesions and the correlation between the primary tumor size, lymph node met...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Xueyang, Chen, Wenjun, Li, Fanfan, Ren, Pengfei, Wu, Hongyang, Zhang, Congjun, Gu, Kangsheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175679/ https://www.ncbi.nlm.nih.gov/pubmed/37188174 http://dx.doi.org/10.3389/fonc.2023.1053125

Ejemplares similares

Conversion of ER, PR, HER2 and Ki-67 and Prognosis in breast cancer metastases to the brain
por: Jiaxin, Chen, et al.
Publicado: (2022)

Prediction of tumor mutation burden in breast cancer based on the expression of ER, PR, HER-2, and Ki-67
por: Xu, Junnan, et al.
Publicado: (2018)

fHER2, PR, ER, Ki-67 and Cytokeratin 5/6 Expression in Benign Feline Mammary Lesions
por: Soares, Maria, et al.
Publicado: (2022)

Discordance in ER, PR, HER2, and Ki-67 Expression Between Primary and Recurrent/Metastatic Lesions in Patients with Primary Early Stage Breast Cancer and the Clinical Significance: Retrospective Analysis of 75 Cases
por: Peng, Li, et al.
Publicado: (2021)

Stromal Expression of CD10 in Invasive Breast Carcinoma and Its Correlation with ER, PR, HER2-neu, and Ki67
por: Puri, Vandana, et al.
Publicado: (2011)

Neoadjuvant chemotherapy reduces the expression rates of ER, PR, HER2, Ki67, and P53 of invasive ductal carcinoma
por: Peng, Jian-Heng, et al.
Publicado: (2019)

Spectrum of meningioma with special reference to prognostic utility of ER,PR and Ki67 expression
por: Mukhopadhyay, Madhumita, et al.
Publicado: (2017)

Neoadjuvant chemotherapy reduces the expression rates of ER, PR, HER2, Ki67, and P53 of invasive ductal carcinoma: Erratum
Publicado: (2022)

ER, PR, HER2, Ki-67 and CK5 in Early and Late Relapsing Breast Cancer—Reduced CK5 Expression in Metastases
por: Joensuu, Kristiina, et al.
Publicado: (2013)

Prognostic significance of Ki67 in Chinese women diagnosed with ER(+)/HER2(−) breast cancers by the 2015 St. Gallen consensus classification
por: Hu, Yue, et al.
Publicado: (2017)

The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines
por: Subik, Kristina, et al.
Publicado: (2010)

Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer
por: Abubakar, Mustapha, et al.
Publicado: (2019)

A Mathematical Model to Predict Diagnostic Periods for Secondary Distant Metastases in Patients with ER/PR/HER2/Ki-67 Subtypes of Breast Cancer
por: Tyuryumina, Ella Ya., et al.
Publicado: (2020)

Breast Carcinoma – A Comparative Study of Immunohistochemistry and Fluorescence in Situ Hybridization for Her-2 Assessment and Association of ER, PR, HER-2 and Ki-67 Expression with Clinico-Pathological Parameters
por: K, Sajitha, et al.
Publicado: (2022)

Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer
por: Sinn, Hans-Peter, et al.
Publicado: (2017)

Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer
por: Gianni, Luca, et al.
Publicado: (2022)

Correlation between ER, PR, HER-2, and Ki-67 with the risk of bone metastases detected by bone scintigraphy in breast cancer patients: A cross sectional study
por: Afkari, Hanif, et al.
Publicado: (2021)

Degree of Resection and Ki-67 Labeling Index for Recurring Meningiomas
por: Menger, Richard, et al.
Publicado: (2017)

A prospective comparison of ER, PR, Ki67 and gene expression in paired sequential core biopsies of primary, untreated breast cancer
por: Hadad, Sirwan M., et al.
Publicado: (2016)

Prognostic and Clinicopathological Value of Ki-67 in Melanoma: A Meta-Analysis
por: Liu, Qixin, et al.
Publicado: (2021)

Prognostic value of inflammatory markers and clinical features for survival in advanced or metastatic esophageal squamous cell carcinoma patients receiving anti-programmed death 1 treatment
por: Da, Liangshan, et al.
Publicado: (2023)

Ki-67 and Its Relation With Complete Pathological Response in Patients With Breast Cancer
por: Wajid, Sana, et al.
Publicado: (2021)

A retrospective study on expression and clinical significance of PHH3, Ki67 and P53 in bladder exophytic papillary urothelial neoplasms
por: Qi, Gaoxiu, et al.
Publicado: (2023)

Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer
por: Burcombe, R J, et al.
Publicado: (2005)

The prognostic significance of p63 and Ki-67 expression in myoepithelial carcinoma
por: Jiang, You-Hua, et al.
Publicado: (2012)

Expression and significance of Her2 and Ki-67 in gastric adenocarcinoma without distant metastasis: a cohort study
por: Wei, Zhijian, et al.
Publicado: (2020)

CT Radiomics Model for Predicting the Ki-67 Index of Lung Cancer： An Exploratory Study
por: Fu, Qing, et al.
Publicado: (2021)

Relationship Between Ultrasound Features and Ki-67 Labeling Index of Soft Tissue Sarcoma
por: Wang, Pingping, et al.
Publicado: (2021)

Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform
por: Wu, Natalie C., et al.
Publicado: (2018)

ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67
por: Tuominen, Vilppu J, et al.
Publicado: (2010)

Interrelationships Between Ki67, HER2/neu, p53, ER, and PR Status and Their Associations With Tumor Grade and Lymph Node Involvement in Breast Carcinoma Subtypes: Retrospective-Observational Analytical Study
por: Shokouh, Taghipour Zahir, et al.
Publicado: (2015)

Based on clinical Ki-67 expression and serum infiltrating lymphocytes related nomogram for predicting the diagnosis of glioma-grading
por: Zhang, Zhi, et al.
Publicado: (2022)

Protein co-expression networks identified from HOT lesions of ER+HER2–Ki-67high luminal breast carcinomas
por: Yamada, Kimito, et al.
Publicado: (2021)

Proliferation Marker Ki67 as a Stratification Index of Adjuvant Chemotherapy for Resectable Mucosal Melanoma
por: Tang, Lirui, et al.
Publicado: (2022)

Clinical Significance of Ki-67 Labeling Index in Pituitary Macroadenoma
por: Paek, Kyung-Il, et al.
Publicado: (2005)

Significance of p53 and ki-67 expression in prostate cancer
por: Verma, Renuka, et al.
Publicado: (2015)

External quality assessment (EQA) program for the immunohistochemical detection of ER, PR and Ki-67 in breast cancer: results of an interlaboratory reproducibility ring study in China
por: Pu, Tianjie, et al.
Publicado: (2019)

Prognostic Value of Ki-67 in Patients With Resected Triple-Negative Breast Cancer: A Meta-Analysis
por: Wu, Qiang, et al.
Publicado: (2019)

Combined Use of cyclinD1 and Ki67 for Prognosis of Luminal-Like Breast Cancer Patients
por: Hao, Junmei, et al.
Publicado: (2021)

Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis
por: Nishimura, Reiki, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_rhphd9l3s5nb7qmsnbr300b2ju